| CASE REPORT |
|
| Year : 2016 | Volume
: 8
| Issue : 4 | Page : 194-196 |
|
|
Tocilizumab efficacy in a patient with positive anti-CCP chronic Lyme arthritis
Julianna Hirsch1, Itzhak Rosner2, Doron Rimar2, Lisa Kaly2, Michael Rozenbaum2, Nina Boulman2, Gleb Slobodin3
1 Department of Medicine, Technion Institute of Technology, Bnai Zion Medical Center, Haifa, Israel
2 Department of Medicine, Technion Institute of Technology; Department of Rheumatology, Bnai Zion Medical Center, Haifa, Israel
3 Department of Medicine, Technion Institute of Technology; Department of Internal Medicine A, Bnai Zion Medical Center, Haifa, Israel
Correspondence Address:
Julianna Hirsch
Faculty of Medicine, Technion Institute of Technology, Haifa, Israel. 32 Hasharon #5 Haifa
Israel
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1947-2714.179960
|
|
|
Context: Lyme arthritis, a manifestation of tick-borne Lyme disease, can prove to be refractory to classic treatment. Case Report: We present a case of a 48-year-old male, diagnosed with chronic Lyme arthritis, refractory to recurrent and prolonged courses of doxycycline, ceftriaxone, as well as hydroxychloroquine and methotrexate. The patient responded partially to tumor necrosis factor (TNF)-alpha blockade by etanercept and, finally, entered long-term remission after his treatment was switched to tocilizumab. Conclusion: Off label treatment by biologic disease modifying antirheumatic drugs can be considered in selected patients with severe antibiotic-resistant Lyme arthritis.C. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
